STTK
Shattuck Labs, Inc.
Overview
Shattuck Labs designs monoclonal and bispecific antibodies targeting the DR3/TL1A immune pathway for inflammatory and immune-mediated diseases. The company's lead candidate, SL-325, is a DR3-blocking antibody in Phase 1 clinical trials for inflammatory bowel disease, with plans to advance to Phase 2 testing in Crohn's disease patients in late 2026.
Shattuck Labs, Inc is a Healthcare company operating in Biotechnology with a $500.5M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 13, 2026).
4 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Earnings history
- Q2 FY20262026-08-13EPS— vs $-0.14—Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-13 | — | $-0.14 | — | — | — | — | EODHD |
Source: EODHD. STTK reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks STTK's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2023 | $3.45 | $4.15 | -16.9% | +4.4% | +4.2% |
| Q4 FY2023 | $3.69 | $4.11 | -10.3% | -1.8% | -4.7% |
| Q3 FY2023 | $3.40 | $4.15 | -18.0% | -2.4% | -4.0% |
| Q2 FY2023 | $3.08 | $3.99 | -22.9% | -0.9% | +0.2% |
| Q1 FY2022 | $3.55 | $4.13 | -14.0% | -0.9% | -1.9% |
| Q4 FY2022 | $3.46 | $4.03 | -14.2% | -0.8% | -1.6% |
| Q3 FY2022 | $3.73 | $4.22 | -11.5% | +1.0% | -1.5% |
| Q2 FY2022 | $3.80 | $4.19 | -9.4% | +1.0% | +0.8% |
| Q1 FY2021 | $3.73 | $4.12 | -9.4% | +1.6% | -1.0% |
| Q4 FY2021 | $3.88 | $4.24 | -8.6% | -0.6% | -1.3% |
Guidance change history
Sample- Q1 FY2023Lowered2023-04-15
- Q4 FY2023Lowered2023-13-15
- Q3 FY2023Lowered2023-10-15
- Q2 FY2023Lowered2023-07-15
- Q1 FY2022Lowered2022-04-15
- Q4 FY2022Lowered2022-13-15
- Q3 FY2022Lowered2022-10-15
- Q2 FY2022Lowered2022-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Taylor SchreiberCEO1 yr 5 mo4 callsCurrentSample
CEO since 2025 • 2/2 beats (100%) • last guidance raise Q1 FY2023
- Andrew R NeillCFO1 yr 5 mo4 callsCurrentSample
CFO since 2025 • 1/2 beats (50%) • last guidance raise Q1 FY2023
- Abhinav A ShuklaChief Technical Officer1 yr 5 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 1/2 beats (50%) • last guidance raise Q2 FY2023
- Arundathy N PanditeChief Medical Officer1 yr 5 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 1/2 beats (50%) • guidance suspended Q1 FY2023
- Casi DeyoungChief Business Officer1 yr 5 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 1/2 beats (50%) • last call held guidance Q1 FY2023
- Stephen StoutSee Remarks1 yr 5 mono recorded callsCurrentSample
OTHER since 2025 • 2/2 beats (100%) • last call held guidance Q1 FY2023
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for STTK.
$ curl https://api.spokenalpha.com/v1/companies/STTKFAQ
Frequently asked about STTK
Where can I find Shattuck Labs, Inc.'s (STTK) earnings call transcripts?
Spoken Alpha indexes STTK's earnings call transcripts at https://spokenalpha.com/companies/STTK. Each call links to attributed speakers and parsed analyst Q&A. Shattuck Labs, Inc.'s own investor relations page is at https://ir.shattucklabs.com/overview/default.aspx.
When was Shattuck Labs, Inc.'s most recent earnings call?
Shattuck Labs, Inc. (STTK) held its most recent earnings call on 2023-11-10, covering fiscal Q3 2023.
What sector is STTK in?
Shattuck Labs, Inc. (STTK) operates in the Healthcare sector (Biotechnology industry).